Northland Securities Begins Coverage on TriSalus Life Sciences (NASDAQ:TLSI)

Investment analysts at Northland Securities assumed coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a report issued on Friday, Briefing.com reports. The firm set an “outperform” rating and a $12.50 price target on the stock. Northland Securities’ price objective would suggest a potential upside of 204.14% from the company’s current price.

TLSI has been the topic of a number of other reports. Canaccord Genuity Group restated a “buy” rating and issued a $12.00 price objective on shares of TriSalus Life Sciences in a research note on Thursday, June 27th. Oppenheimer initiated coverage on TriSalus Life Sciences in a report on Monday, September 16th. They issued an “outperform” rating and a $10.00 price target for the company. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $12.50.

TriSalus Life Sciences Trading Up 2.0 %

TriSalus Life Sciences stock opened at $4.11 on Friday. The company has a fifty day simple moving average of $4.77 and a 200-day simple moving average of $6.44. The stock has a market cap of $120.46 million, a P/E ratio of -1.64 and a beta of 0.47. TriSalus Life Sciences has a 12-month low of $3.32 and a 12-month high of $10.42.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.21) earnings per share for the quarter. The company had revenue of $7.36 million for the quarter. As a group, sell-side analysts forecast that TriSalus Life Sciences will post -1.53 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Mary T. Szela bought 7,520 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were acquired at an average cost of $5.20 per share, with a total value of $39,104.00. Following the transaction, the chief executive officer now owns 377,382 shares of the company’s stock, valued at $1,962,386.40. This represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 32.80% of the company’s stock.

Hedge Funds Weigh In On TriSalus Life Sciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Wolverine Asset Management LLC purchased a new stake in shares of TriSalus Life Sciences during the 2nd quarter valued at about $240,000. Highbridge Capital Management LLC acquired a new stake in shares of TriSalus Life Sciences during the second quarter valued at about $1,184,000. Finally, Duquesne Family Office LLC increased its holdings in TriSalus Life Sciences by 35.1% during the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after purchasing an additional 110,966 shares during the last quarter. 2.58% of the stock is owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.